We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule
News

Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule

Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule
News

Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Santaris Pharma has announced the completion of the delivery of six cancer target drug candidates to their collaboration partner Enzon Pharmaceuticals. All six drug candidates have been designed, synthesized and selected in collaboration with Enzon, within 24 months of commencing the collaboration.

"Our collaboration with Enzon Pharmaceuticals has been very productive and goal oriented enabling both companies to benefit optimally from our ability to rationally design, discover and select potent and safe RNA targeted drugs within a short time span," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer.

Santaris Pharma and Enzon Pharmaceuticals signed their agreement in 2006. As part of the agreement Santaris Pharma retains the lucrative commercial rights to the drugs within Europe.

The agreement included two LNA based RNA inhibitors at the pre-clinical stage, EZN2968 against HIF-1α, and EZN3042 against Survivin, both of which are currently in Phase I studies conducted by Enzon, and the development of six additional cancer target drugs selected by Enzon which are in various stages of preclinical development.

"We are encouraged by the data generated by the first two lead candidates," said Dr. Ivan Horak, Executive Vice President of Research, Development and Chief Scientific Officer, Enzon Pharmaceuticals. "In addition, I'm pleased to see the continued validation of the Locked Nucleic Acid (LNA) technology as we continue to evaluate the additional targets in preclinical programs."
Advertisement